Breaking News

PPD to Complete OBI’s Oxycyte Trial

November 20, 2012

Will evaluate safety and tolerability in traumatic brain injury

Oxygen Biotherapeutics, Inc. has partnered with PPD to conduct its Phase IIb trial, STOP-TBI (Safety and Tolerability of Oxycyte in Patients with Severe non-Penetrating Traumatic Brain Injury). The trial will evaluate the safety and tolerability of a single administration of Oxycyte in patients with severe non-penetrating traumatic brain injury. The secondary objective is to assess the potential of Oxycyte in improving the severity of TBI.
Dr. Timothy Bradshaw, executive vice president of Drug Development at OBI, said, “We are pleased to be working with PPD as our CRO to oversee the completion of this critical trial. We selected PPD for their global reach and expertise conducting trials in which critically injured subjects are identified and managed in an emergency or trauma setting. They have presented a great operational plan for ensuring the successful completion of the study. In addition, PPD has medical staff with therapeutic expertise in neurotrauma. Our focus now is getting sites ready to enroll patients.”

Related Compliance:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.